Breaking News

Emergex files patent in US for novel pandemic flu vaccine

The patent, ‘Reverse Peptide Vaccines’, covers the use of peptides derived from human influenza A

Scancell receives European patent for immunotherapy platform

The developer of novel immunotherapies confirmed that the European Patent Office will grant a European Patent for its ...

Emergex receives Innovate UK Grant to progress flu vaccine

The biotechnology company, which is aiming to find a new approach to vaccine development, has received a grant to ...

Move toward cell-based manufacturing signals opening in vaccine market

Global investments and initiatives by governmental and non-governmental organisations are bringing considerable growth ...

GE accelerates production of viral vector based therapeutics

GE Healthcare has launched a new factory-in-a-box, designed to accelerate the manufacture of products requiring a ...

Merck helps accelerate global access to affordable vaccines

Merck, a leading science and technology company, has announced a partnership with Oxford University’s Jenner Institute ...

Sanofi to invest €350 million in Canadian vaccine facility

Expansion demonstrates company's commitment to innovation and leadership in global public health

Emergex progresses its synthetic vaccine development pipeline

Pioneering a simple, inexpensive and fast approach to vaccine development using 100% synthetic vaccine constructs to ...

Using electrons to inactivate viruses in vaccines

Four institutes associated with the Fraunhofer Gesellschaft in Germany have been investigating new techniques to make ...

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah ...

Bavarian Nordic partners with US DoD to combat equine encephalitis

Signing of a new alliance for the development of a prophylactic vaccine against the equine encephalitis virus

Poor flu vaccine efficacy necessitates manufacturing shift

According to GlobalData, a data and analytics company, the poor seasonal influenza vaccine efficacy means a shift away ...